Comparative in vivo and in vitro study of the cytogenetic effects of 153Sm-EDTMP in lymphocytes of patients with bone metastases.
153Sm-EDTMP is a radiopharmaceutical used in nuclear medicine for relief of metastatic bone pain with promising results, but there are few studies about the effects of 153Sm-EDTMP in human cells. This study was conducted for the evaluation of the cytogenetic effects of 153Sm-EDTMP in blood lymphocytes from patients with bone metastases (without previous radio or chemotherapy), using the chromosome aberration technique. The degree of cytological damage found in in vivo blood cells of patients was compared with those found in in vitro in an adjusted dose-response curve. Blood samples were collected before and 1 hr after the administration of 153Sm-EDTMP(about 42.31 MBq/kg). The frequency of structural chromosome aberration per cell observed in 1 hr samples (0.054+/-0.035 CA/cell) was higher than basal ones (0.031+/-0.026 CA/cell), although this difference was not statistically significant (p= 0.101). For in vitro assay, blood samples were exposed to different concentrations of 153Sm-EDTMP, during 1 hr (0.37-1.11 MBq/ml). An increase in the frequency of chromosome aberration per cell as a function of the radioactive concentration was found. The data were adjusted by linear regression model (Y= 3.52+/-2.24 x 10(-2) + 11.15+/-3.46 x 10(-2) X). The frequency of aberration/cell found in vivo was 0.054 and for the same activity in vitro was 0.098, this difference being statistically significant (p = 0.02). This result may be related to blood clearance, osteoblastic activity and individual variability. For a more accurate analysis, the study of more donors is necessary.
da Silva
Márcia Augusta
MA
Instituto de Pesquisas Energéticas e Nucleares IPEN, CNEN-SP, Departamento de Metrologia das Radiações, Cidade Universitária, Pinheiros, São Paulo, SP, Brazil. masilva@net.ipen.br
Suzuki
Miriam Fussae
MF
Guimarães
Maria Inês C C
MI
Buchpiguel
Carlos Alberto
CA
Rogero
José Roberto
JR
Yoriyaz
Hélio
H
Siqueira
Paulo Tarso D
PT
Coelho
Paulo Rogério P
PR
Okazaki
Kayo
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001773:Blood Cells / Q000528:radiation effects; D001859:Bone Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000556:secondary; D016022:Case-Control Studies; D002869:Chromosome Aberrations / Q000528:radiation effects; D020732:Cytogenetic Analysis; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010146:Pain / Q000209:etiology / Q000532:radiotherapy
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam